Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyBenzydamine
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Benzydamine
- Accession Number
- DB09084
- Type
- Small Molecule
- Groups
- Approved
- Description
Benzydamine (also known as Tantum Verde and branded in some countries as Difflam), available as the hydrochloride salt, is a locally-acting nonsteroidal anti-inflammatory drug (NSAID) with local anaesthetic and analgesic properties for pain relief and anti-inflammatory treatment of typically topical inflammatory conditions associated with the mouth, throat, or muscoskeletal locations.
Although the indazole analogue benzydamine is a non-steroidal anti-inflammatory drug (NSAID), it has various physicochemical properties and pharmacologic activities that are different from those of traditional aspirin-like NSAIDs but facilitate benzydamine's mechanism of action as an effective locally-acting NSAID with local anaesthetic and analgesic properties. Moreover, unlike aspirin-like NSAIDs which are acids or metabolised to acids, benzydamine is in fact a weak base.
- Structure
Structure for DB09084 (Benzydamine)
- Synonyms
- Not Available
- Product Ingredients
Ingredient UNII CAS InChI Key Benzydamine hydrochloride K2GI407R4Q 132-69-4 HNNIWKQLJSNAEQ-UHFFFAOYSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Pharixia Mouthwash 1.5 mg Buccal Pendopharm Division Of De Pharmascience Inc 1996-12-02 Not applicable Canada 
Sun-benz - Liq 0.15% Liquid .15 % Dental; Oral Sun Pharmaceutical Industries Limited 1997-04-03 2011-07-29 Canada Tantum Solution 15 mg Buccal Valeant Canada Lp Valeant Canada S.E.C. 1993-12-31 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-benzydamine Oral Rinse Liquid 0.15 % Buccal Apotex Corporation 1998-11-09 Not applicable Canada Novo-benzydamine Mouthwash; Solution 1.5 mg Buccal; Oral Novopharm Limited 2008-06-03 Not applicable Canada Novo-benzydamine - Oral Rinse Liquid; Mouthwash 1.5 mg Buccal; Oral Novopharm Limited 1997-02-06 2015-10-26 Canada Nu-benzydamine Oral Rinse Liquid 0.15 % Buccal Nu Pharm Inc Not applicable Not applicable Canada Odan-benzydamine Mouthwash 1.5 mg Buccal Odan Laboratories Ltd 2017-08-11 Not applicable Canada PMS-benzydamine Mouthwash 1.5 mg Buccal Pharmascience Inc 1999-04-30 Not applicable Canada Ratio-benzydamine Solution 0.15 % Oral Ratiopharm Inc Division Of Teva Canada Limited 1997-03-24 2010-05-21 Canada - Categories
- UNII
- 4O21U048EF
- CAS number
- 642-72-8
- Weight
- Average: 309.413
Monoisotopic: 309.184112373 - Chemical Formula
- C19H23N3O
- InChI Key
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H23N3O/c1-21(2)13-8-14-23-19-17-11-6-7-12-18(17)22(20-19)15-16-9-4-3-5-10-16/h3-7,9-12H,8,13-15H2,1-2H3
- IUPAC Name
- {3-[(1-benzyl-1H-indazol-3-yl)oxy]propyl}dimethylamine
- SMILES
- CN(C)CCCOC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12
Pharmacology
- Indication
Available predominantly as a liquid mouthwash, oromucosal spray, or topical cream, benzydamine is most frequently employed as a locally acting analgesic and anti-inflammatory treatment for the relief of painful inflammatory conditions.
When formulated as a mouthwash or spray, benzydamine may be used to treat traumatic conditions like pharyngitis following tonsillectomy or the use of a naso-gastric tube, inflammatory conditions like pharyngitis, aphthous ulcers and oral ulceration due to radiation therapy, dentistry operations and procedures, or more general conditions like sore throat, sore tongue, sore gums, mouth ulcers, or discomfort caused by dentures. [6]
When used as a topical cream, benzydamine may be employed to relieve symptoms associated with painful inflammatory conditions of the muscolo-skeletal system including acute inflammatory disorders such as myalgia and bursitis or traumatic conditions like sprains, strains, bruises, sore muscles, stiff joints, or even the after-effects of fractures. [7]
- Structured Indications
- Pharmacodynamics
Benzydamine is a non-steroidal anti-inflammatory drug (NSAID) designed to elicit local anesthetic and analgesic effects mainly for the mouth and throat. It specifically acts on the local mechanisms of inflammation such as pain, oedema, or granuloma. Typically applied topically, the drug demonstrates anti-inflammatory activity reducing oedema as well as exudate and granuloma formation. Moreover, benzydamine exhibits analgesic properties and local anaesthetic activity if pain is caused by an inflammatory condition. Benzydamine can be absorbed into the oral mucosa and intact skin. Once absorbed in the local area of pain or inflammation, benzydamine binds selectively to local inflamed tissues, usually allowing it to act with few adverse systemic effects. On average a period of 2 to 4 hours is necessary for the substance to reach peak plasma concentration. [5]
Benzydamine can be synthesized with the reaction of the N-benzyl derivative from methyl anthranilate with nitrous acid to give N-nitoso derivative. This is next reduced by sodium thiosulfate to give transient hydrazine. This hydrazine can then undergo spontaneous internal hydrazide formation. Treating this resultant enolate with 3-chloro-1-dimethylamkino propane ultimately yields benzydamine.
- Mechanism of action
Despite being categorized as a non-steroidal anti-inflammatory drug (NSAID), benzydamine demonstrates various mechanisms of action that differ from those of traditional aspirin-like NSAIDs. In particular, benzydamine predominantly acts by inhibiting the synthesis of pro inflammatory cytokines like tumour necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β) without largely affecting other pro inflammatory cytokines (ie. such as IL-6 and IL-8) or anti-inflammatory cytokines (ie. like IL-10 or IL-1 receptor antagonist). [3, 5]
Moreover, benzydamine is largely a weak inhibitor of prostaglandin synthesis as it has been shown to effectively inhibit cyclooxygenase (COX) and lipoxygenase enzyme activity only at concentrations of 1mM or greater. Considering most contemporary usages of benzydamine are topical applications that are generally not well absorbed through the skin and/or non-specialized mucosae, benzydamine does not often achieve the kind of absorption or blood concentrations necessary to cause any extraneous distant systemic effects or COX inhibition, allowing it to localize its action. [3, 5]
Additionally, it is also hypothesized that benzydamine is capable of inhibiting the oxidative burst of neutrophils and membrane stabilization. These actions are exhibited by the substance’s ability to inhibit the release of granules from neutrophils and to stabilize lysosomes. [3, 5]
Furthermore, benzydamine is capable of a local anaesthetic effect that may be related to its capability for inhibiting the release of inflammatory mediators like substance P and calcitonin gene related peptide from sensory nerve endings. Since substance P is capable of causing the release of histamine from mast cells, benzydamine’s prevention of substance P release further contributes to an anti-inflammatory effect. [3, 5]
Benzydamine also demonstrates a non-specific antibacterial activity against various bacterial strains that are resistant to broad-spectrum antibiotics such as ampicillin, chloramphenicol, and tetracycline at concentrations of about 3 mmol/L. Combinatorial use of benzydamine and other antibiotics like tetracycline and chloramphenicol are also synergistic against antibiotic resistant strains of Staphylococcus aureus and Pseudomonas aeruginosa. [3]
- Absorption
Oral doses of benzydamine are well absorbed and plasma drug concentrations reach a peak fairly rapidly and then decline with a half-life of approximately 13 hours. When applied topically, although the local drug concentrations are relatively large, the systemic absorption of topically applied benzydamine is relatively low compared to oral doses. This low topical absorption contributes to a decreased potential for any systemic drug side-effects when benzydamine is administered in this way. [6]
- Volume of distribution
- Protein binding
Benzydamine exhibits < 20% plasma protein binding after oral administration [6, 3].
- Metabolism
Benzydamine is primarily metabolised by oxidation, dealkylation, and conjugation into hydroxy, dealkylated, and N-oxide metaboiltes [6, 3].
- Route of elimination
The relatively high lipid solubility of the weak base benzydamine is thought to be associated with considerable passive resorption within the renal tubule, which suggests that only approximately 5% of benzydamine is excreted unchanged in the urine [1]. At the same time however, other studies have suggested that considerably larger amounts (50-65%) of the drug is excreted unchanged in urine [4].
While several inactive oxidized metabolites of benzydamine are excreted in urine, the benzydamine N-oxide metabolite can remain in plasma and demonstrate a half-life that is longer than the parent benzydamine compound [1].
- Half life
Approximately 13 h after oral administration [6], with a terminal half life of about 7.7 h [3].
- Clearance
Benzydamine demonstrateas a systemic clearance of 170 ml/min [3].
- Toxicity
A possible adverse reaction associated with the use of the mouthwash or oromucosal spray formulations of benzymadine is potential numbness and/or stinging in the mouth and/or throat [5, 6].
Some possible adverse reactions that tend to be associated more with topical cream formulations of benzymadine include increased sensitivity to sunlight, and localized itching, skin rash, redness, or swelling [7].
The prescribing information for all formulations of benzymadine however, warn against the possibility of severe allergic reaction (anaphylaxis) associated with swelling of the throat and mouth, difficulty in swallowing, speaking, and breathing, or wheezing [5, 6, 7].
As benzydamine is a non-steroidal anti-inflammatory drug (NSAID), it is necessary to determine if a patient is allergic to NSAIDs before considering its use [5, 6, 7].
Intoxication is expected as a consequence of accidental ingestion of large quantities of benzydamine (over 300 mg ingestion). Other symptoms associated with overdose of ingested benzydamine include gastrointestinal and central nervous system symptoms like nausea, vomiting, abdominal pain, oesophageal irritation, dizziness, hallucinations, agitation, anxiety, and irritability [6].
The official prescribing information for benzydamine generally suggest that benzydamine mouthwashes and sprays should not be used in pregnancy [6, 7] . Similarly, the official prescribing information for benzydamine also generally suggest that benzydamine mouthwashes and sprays should not be used during lactation unless considered essential by a physician [6, 7].
The prescribing information for topical cream formulations of benzydamine note that benzydamine cream should not be used in pregnancy or lactation unless considered necessary by the physician [5].
Overall, non-clinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeated toxicity, genotoxicity, cardiogenic potential, and toxicity to reproduction [5]. Additionally, there is no evidence of teratogenic effects in animal studies [6].
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Benzydamine. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when Benzydamine is combined with 16-Bromoepiandrosterone. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when Benzydamine is combined with 19-norandrostenedione. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when Benzydamine is combined with 5-androstenedione. Experimental, Illicit Abciximab Benzydamine may increase the anticoagulant activities of Abciximab. Approved Acebutolol Benzydamine may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Benzydamine. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Benzydamine is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Benzydamine may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Benzydamine. Approved, Vet Approved Aclarubicin Benzydamine may decrease the excretion rate of Aclarubicin which could result in a higher serum level. Investigational Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Benzydamine. Approved Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Benzydamine. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Benzydamine is combined with Alclometasone. Approved Aldosterone The risk or severity of adverse effects can be increased when Benzydamine is combined with Aldosterone. Experimental, Investigational Aldoxorubicin Benzydamine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Alendronic acid The risk or severity of adverse effects can be increased when Benzydamine is combined with Alendronic acid. Approved Aliskiren Benzydamine may decrease the antihypertensive activities of Aliskiren. Approved, Investigational Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Benzydamine. Experimental Alprenolol Benzydamine may decrease the antihypertensive activities of Alprenolol. Approved, Withdrawn Alprostadil The therapeutic efficacy of Alprostadil can be decreased when used in combination with Benzydamine. Approved, Investigational Amcinonide The risk or severity of adverse effects can be increased when Benzydamine is combined with Amcinonide. Approved Amikacin Benzydamine may decrease the excretion rate of Amikacin which could result in a higher serum level. Approved, Investigational, Vet Approved Amiloride Benzydamine may decrease the antihypertensive activities of Amiloride. Approved Amrubicin Benzydamine may decrease the excretion rate of Amrubicin which could result in a higher serum level. Approved, Investigational Ancrod Benzydamine may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Benzydamine. Investigational Androstenedione The risk or severity of adverse effects can be increased when Benzydamine is combined with Androstenedione. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Benzydamine is combined with Anecortave. Investigational anecortave acetate The risk or severity of adverse effects can be increased when Benzydamine is combined with anecortave acetate. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Benzydamine. Investigational Annamycin Benzydamine may decrease the excretion rate of Annamycin which could result in a higher serum level. Investigational Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Benzydamine. Approved, Investigational Antithrombin III human Benzydamine may increase the anticoagulant activities of Antithrombin III human. Approved Apixaban Benzydamine may increase the anticoagulant activities of Apixaban. Approved Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Benzydamine. Investigational Apramycin Benzydamine may decrease the excretion rate of Apramycin which could result in a higher serum level. Experimental, Vet Approved Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Benzydamine. Approved, Investigational Arbekacin Benzydamine may decrease the excretion rate of Arbekacin which could result in a higher serum level. Approved, Investigational Ardeparin Benzydamine may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Benzydamine may increase the anticoagulant activities of Argatroban. Approved, Investigational Arotinolol Benzydamine may decrease the antihypertensive activities of Arotinolol. Investigational Atamestane The risk or severity of adverse effects can be increased when Benzydamine is combined with Atamestane. Investigational Atenolol Benzydamine may decrease the antihypertensive activities of Atenolol. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Benzydamine. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Benzydamine. Approved Azficel-T The risk or severity of adverse effects can be increased when Benzydamine is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Benzydamine. Approved, Investigational Azosemide The therapeutic efficacy of Azosemide can be decreased when used in combination with Benzydamine. Investigational Balsalazide Benzydamine may increase the nephrotoxic activities of Balsalazide. Approved, Investigational Becaplermin Benzydamine may increase the anticoagulant activities of Becaplermin. Approved, Investigational Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Benzydamine is combined with Beclomethasone dipropionate. Approved, Investigational Befunolol Benzydamine may decrease the antihypertensive activities of Befunolol. Experimental Bekanamycin Benzydamine may decrease the excretion rate of Bekanamycin which could result in a higher serum level. Experimental Benazepril The risk or severity of adverse effects can be increased when Benzydamine is combined with Benazepril. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Benzydamine. Experimental Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Benzydamine. Approved Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Benzydamine. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Benzydamine. Withdrawn Beraprost The therapeutic efficacy of Beraprost can be decreased when used in combination with Benzydamine. Investigational Betamethasone The risk or severity of adverse effects can be increased when Benzydamine is combined with Betamethasone. Approved, Vet Approved Betaxolol Benzydamine may decrease the antihypertensive activities of Betaxolol. Approved, Investigational Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Benzydamine. Approved, Investigational Bevantolol Benzydamine may decrease the antihypertensive activities of Bevantolol. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Benzydamine. Experimental Bimatoprost The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Benzydamine. Approved, Investigational Bisoprolol Benzydamine may decrease the antihypertensive activities of Bisoprolol. Approved Bivalirudin Benzydamine may increase the anticoagulant activities of Bivalirudin. Approved, Investigational Bopindolol Benzydamine may decrease the antihypertensive activities of Bopindolol. Approved Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Benzydamine. Approved Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Benzydamine. Investigational Bucindolol Benzydamine may decrease the antihypertensive activities of Bucindolol. Investigational Budesonide The risk or severity of adverse effects can be increased when Benzydamine is combined with Budesonide. Approved Bufexamac The risk or severity of adverse effects can be increased when Bufexamac is combined with Benzydamine. Approved, Experimental Bufuralol Benzydamine may decrease the antihypertensive activities of Bufuralol. Experimental, Investigational Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Benzydamine. Experimental Bumetanide The therapeutic efficacy of Bumetanide can be decreased when used in combination with Benzydamine. Approved Bupranolol Benzydamine may decrease the antihypertensive activities of Bupranolol. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Benzydamine. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Benzydamine. Approved Candoxatril The risk or severity of adverse effects can be increased when Benzydamine is combined with Candoxatril. Experimental Captopril The risk or severity of adverse effects can be increased when Benzydamine is combined with Captopril. Approved Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Benzydamine. Experimental, Investigational Carboprost Tromethamine The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Benzydamine. Approved Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Benzydamine. Approved, Vet Approved, Withdrawn Carteolol Benzydamine may decrease the antihypertensive activities of Carteolol. Approved Carvedilol Benzydamine may decrease the antihypertensive activities of Carvedilol. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Benzydamine. Experimental Celecoxib The risk or severity of adverse effects can be increased when Benzydamine is combined with Celecoxib. Approved, Investigational Celiprolol Benzydamine may decrease the antihypertensive activities of Celiprolol. Approved, Investigational Certoparin Benzydamine may increase the anticoagulant activities of Certoparin. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Benzydamine. Approved, Investigational, Vet Approved Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Benzydamine. Approved, Vet Approved Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Benzydamine. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Benzydamine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Benzydamine. Approved Ciclesonide The risk or severity of adverse effects can be increased when Benzydamine is combined with Ciclesonide. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when Benzydamine is combined with Cilazapril. Approved Cinoxacin Benzydamine may increase the neuroexcitatory activities of Cinoxacin. Approved, Investigational, Withdrawn Citric Acid Benzydamine may increase the anticoagulant activities of Citric Acid. Approved, Nutraceutical, Vet Approved Clobetasol The risk or severity of adverse effects can be increased when Benzydamine is combined with Clobetasol. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Benzydamine is combined with Clobetasol propionate. Approved Clobetasone The risk or severity of adverse effects can be increased when Benzydamine is combined with Clobetasone. Approved Clocortolone The risk or severity of adverse effects can be increased when Benzydamine is combined with Clocortolone. Approved Clodronic Acid The risk or severity of adverse effects can be increased when Benzydamine is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Benzydamine. Approved Cloprostenol The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Benzydamine. Vet Approved Cloranolol Benzydamine may decrease the antihypertensive activities of Cloranolol. Experimental Colesevelam Colesevelam can cause a decrease in the absorption of Benzydamine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Benzydamine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Benzydamine is combined with Cortexolone 17α-propionate. Investigational Corticosterone The risk or severity of adverse effects can be increased when Benzydamine is combined with Corticosterone. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Benzydamine is combined with Cortisone acetate. Approved, Investigational Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Benzydamine. Approved, Investigational Cyclopenthiazide The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Benzydamine. Experimental Cyclosporine Benzydamine may increase the nephrotoxic activities of Cyclosporine. Approved, Investigational, Vet Approved Dabigatran etexilate Benzydamine may increase the anticoagulant activities of Dabigatran etexilate. Approved Dalteparin Benzydamine may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Benzydamine may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban Benzydamine may increase the anticoagulant activities of Darexaban. Investigational Daunorubicin Benzydamine may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Approved Deferasirox The risk or severity of adverse effects can be increased when Benzydamine is combined with Deferasirox. Approved, Investigational Deflazacort The risk or severity of adverse effects can be increased when Benzydamine is combined with Deflazacort. Approved, Investigational Delapril The risk or severity of adverse effects can be increased when Benzydamine is combined with Delapril. Experimental Desirudin Benzydamine may increase the anticoagulant activities of Desirudin. Approved Desmopressin The risk or severity of adverse effects can be increased when Benzydamine is combined with Desmopressin. Approved Desonide The risk or severity of adverse effects can be increased when Benzydamine is combined with Desonide. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Benzydamine is combined with Desoximetasone. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Benzydamine is combined with Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Benzydamine is combined with Desoxycorticosterone Pivalate. Experimental, Vet Approved Dexamethasone The risk or severity of adverse effects can be increased when Benzydamine is combined with Dexamethasone. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Benzydamine is combined with Dexamethasone isonicotinate. Vet Approved Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Benzydamine. Approved, Investigational Dextran Benzydamine may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dextran 40 Benzydamine may increase the anticoagulant activities of Dextran 40. Approved Dextran 70 Benzydamine may increase the anticoagulant activities of Dextran 70. Approved Dextran 75 Benzydamine may increase the anticoagulant activities of Dextran 75. Approved Dibekacin Benzydamine may decrease the excretion rate of Dibekacin which could result in a higher serum level. Experimental Dibotermin alfa The risk or severity of adverse effects can be increased when Benzydamine is combined with Dibotermin alfa. Approved, Investigational Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Benzydamine. Approved, Vet Approved Dicoumarol Benzydamine may increase the anticoagulant activities of Dicoumarol. Approved Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Benzydamine. Experimental Diflorasone The risk or severity of adverse effects can be increased when Benzydamine is combined with Diflorasone. Approved Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Benzydamine. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Benzydamine is combined with Difluocortolone. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Benzydamine is combined with Difluprednate. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Benzydamine. Approved Dihydrostreptomycin Benzydamine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. Investigational, Vet Approved Dinoprost The therapeutic efficacy of Dinoprost can be decreased when used in combination with Benzydamine. Investigational Dinoprost Tromethamine The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Benzydamine. Approved, Vet Approved Dinoprostone The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Benzydamine. Approved Doxorubicin Benzydamine may decrease the excretion rate of Doxorubicin which could result in a higher serum level. Approved, Investigational Drospirenone Benzydamine may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Droxicam is combined with Benzydamine. Withdrawn Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Benzydamine. Investigational E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Benzydamine. Investigational Edetic Acid Benzydamine may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Benzydamine may increase the anticoagulant activities of Edoxaban. Approved Enalapril The risk or severity of adverse effects can be increased when Benzydamine is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Benzydamine is combined with Enalaprilat. Approved Enoxacin Benzydamine may increase the neuroexcitatory activities of Enoxacin. Approved, Investigational Enoxaparin Benzydamine may increase the anticoagulant activities of Enoxaparin. Approved Enprostil The therapeutic efficacy of Enprostil can be decreased when used in combination with Benzydamine. Experimental Epanolol Benzydamine may decrease the antihypertensive activities of Epanolol. Experimental Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Benzydamine. Approved Epirubicin Benzydamine may decrease the excretion rate of Epirubicin which could result in a higher serum level. Approved Epitizide The therapeutic efficacy of Epitizide can be decreased when used in combination with Benzydamine. Experimental Eplerenone Benzydamine may decrease the antihypertensive activities of Eplerenone. Approved Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Benzydamine. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Benzydamine. Approved Equilenin The risk or severity of adverse effects can be increased when Benzydamine is combined with Equilenin. Experimental Equilin The risk or severity of adverse effects can be increased when Benzydamine is combined with Equilin. Approved Esmolol Benzydamine may decrease the antihypertensive activities of Esmolol. Approved Estrone The risk or severity of adverse effects can be increased when Benzydamine is combined with Estrone. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Benzydamine is combined with Estrone sulfate. Approved Etacrynic acid The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Benzydamine. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Benzydamine. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Benzydamine. Experimental Ethyl biscoumacetate Benzydamine may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etidronic acid The risk or severity of adverse effects can be increased when Benzydamine is combined with Etidronic acid. Approved Etodolac The risk or severity of adverse effects can be increased when Benzydamine is combined with Etodolac. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Benzydamine. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Benzydamine is combined with Etoricoxib. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Benzydamine. Approved, Investigational Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Benzydamine. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Benzydamine. Experimental Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Benzydamine. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Benzydamine. Approved Fenprostalene The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Benzydamine. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Benzydamine. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Benzydamine. Experimental Ferulic acid Benzydamine may increase the anticoagulant activities of Ferulic acid. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Benzydamine. Approved, Investigational Fleroxacin Benzydamine may increase the neuroexcitatory activities of Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Benzydamine. Approved, Withdrawn Fluasterone The risk or severity of adverse effects can be increased when Benzydamine is combined with Fluasterone. Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Benzydamine is combined with Fludrocortisone. Approved, Investigational Fluindione Benzydamine may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine Benzydamine may increase the neuroexcitatory activities of Flumequine. Withdrawn Flumethasone The risk or severity of adverse effects can be increased when Benzydamine is combined with Flumethasone. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Benzydamine is combined with Flunisolide. Approved, Investigational Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Benzydamine. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Benzydamine. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Benzydamine is combined with Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Benzydamine is combined with Fluocinonide. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Benzydamine is combined with Fluocortolone. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Benzydamine is combined with Fluorometholone. Approved, Investigational Fluprednidene The risk or severity of adverse effects can be increased when Benzydamine is combined with Fluprednidene. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Benzydamine is combined with Fluprednisolone. Approved Fluprostenol The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Benzydamine. Vet Approved Flurandrenolide The risk or severity of adverse effects can be increased when Benzydamine is combined with Flurandrenolide. Approved Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Benzydamine. Approved, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Benzydamine is combined with Fluticasone furoate. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Benzydamine is combined with Fluticasone propionate. Approved Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with Benzydamine. Approved, Nutraceutical, Vet Approved Fondaparinux Benzydamine may increase the anticoagulant activities of Fondaparinux. Approved, Investigational Fondaparinux sodium Benzydamine may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Benzydamine. Experimental Formestane The risk or severity of adverse effects can be increased when Benzydamine is combined with Formestane. Approved, Investigational, Withdrawn Fosinopril The risk or severity of adverse effects can be increased when Benzydamine is combined with Fosinopril. Approved Framycetin Benzydamine may decrease the excretion rate of Framycetin which could result in a higher serum level. Approved Furosemide The therapeutic efficacy of Furosemide can be decreased when used in combination with Benzydamine. Approved, Vet Approved Gabexate Benzydamine may increase the anticoagulant activities of Gabexate. Investigational Garenoxacin Benzydamine may increase the neuroexcitatory activities of Garenoxacin. Investigational Gatifloxacin Benzydamine may increase the neuroexcitatory activities of Gatifloxacin. Approved, Investigational Gemeprost The therapeutic efficacy of Gemeprost can be decreased when used in combination with Benzydamine. Approved, Withdrawn Gemifloxacin Benzydamine may increase the neuroexcitatory activities of Gemifloxacin. Approved, Investigational Geneticin Benzydamine may decrease the excretion rate of Geneticin which could result in a higher serum level. Experimental Gentamicin Benzydamine may decrease the excretion rate of Gentamicin which could result in a higher serum level. Approved, Vet Approved GENTAMICIN C1A Benzydamine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. Experimental GPX-150 Benzydamine may decrease the excretion rate of GPX-150 which could result in a higher serum level. Investigational Grepafloxacin Benzydamine may increase the neuroexcitatory activities of Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with Benzydamine. Experimental Halcinonide The risk or severity of adverse effects can be increased when Benzydamine is combined with Halcinonide. Approved, Investigational, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Benzydamine is combined with Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when Benzydamine is combined with HE3286. Investigational Heparin Benzydamine may increase the anticoagulant activities of Heparin. Approved, Investigational Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Benzydamine. Investigational Hydralazine Benzydamine may decrease the antihypertensive activities of Hydralazine. Approved Hydrochlorothiazide The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Benzydamine. Approved, Vet Approved Hydrocortisone The risk or severity of adverse effects can be increased when Benzydamine is combined with Hydrocortisone. Approved, Vet Approved Hydroflumethiazide The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Benzydamine. Approved, Investigational Hygromycin B Benzydamine may decrease the excretion rate of Hygromycin B which could result in a higher serum level. Vet Approved Ibandronate The risk or severity of adverse effects can be increased when Benzydamine is combined with Ibandronate. Approved, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Benzydamine. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Benzydamine. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Benzydamine. Approved, Investigational Idarubicin Benzydamine may decrease the excretion rate of Idarubicin which could result in a higher serum level. Approved Idraparinux Benzydamine may increase the anticoagulant activities of Idraparinux. Investigational Iloprost The therapeutic efficacy of Iloprost can be decreased when used in combination with Benzydamine. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Benzydamine is combined with Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Benzydamine. Experimental Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Benzydamine. Approved Indenolol Benzydamine may decrease the antihypertensive activities of Indenolol. Withdrawn Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Benzydamine. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Benzydamine. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Benzydamine. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Benzydamine. Approved, Investigational Isepamicin Benzydamine may decrease the excretion rate of Isepamicin which could result in a higher serum level. Experimental Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Benzydamine. Withdrawn Istaroxime The risk or severity of adverse effects can be increased when Benzydamine is combined with Istaroxime. Investigational Kanamycin Benzydamine may decrease the excretion rate of Kanamycin which could result in a higher serum level. Approved, Investigational, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Benzydamine. Experimental Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Benzydamine. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Benzydamine. Approved Labetalol Benzydamine may decrease the antihypertensive activities of Labetalol. Approved Landiolol Benzydamine may decrease the antihypertensive activities of Landiolol. Investigational Latanoprost The therapeutic efficacy of Latanoprost can be decreased when used in combination with Benzydamine. Approved, Investigational Latanoprostene Bunod The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Benzydamine. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Benzydamine. Approved, Investigational Lepirudin Benzydamine may increase the anticoagulant activities of Lepirudin. Approved Letaxaban Benzydamine may increase the anticoagulant activities of Letaxaban. Investigational Levobunolol Benzydamine may decrease the antihypertensive activities of Levobunolol. Approved Levofloxacin Benzydamine may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Limaprost The therapeutic efficacy of Limaprost can be decreased when used in combination with Benzydamine. Approved, Investigational Lisinopril The risk or severity of adverse effects can be increased when Benzydamine is combined with Lisinopril. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Benzydamine. Investigational Lithium The serum concentration of Lithium can be increased when it is combined with Benzydamine. Approved Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Benzydamine. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Benzydamine. Approved, Investigational Losartan The risk or severity of adverse effects can be increased when Losartan is combined with Benzydamine. Approved Loteprednol The risk or severity of adverse effects can be increased when Benzydamine is combined with Loteprednol. Approved Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Benzydamine. Approved, Investigational Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Benzydamine. Approved, Investigational Lumiracoxib The risk or severity of adverse effects can be increased when Benzydamine is combined with Lumiracoxib. Approved, Investigational Luprostiol The therapeutic efficacy of Luprostiol can be decreased when used in combination with Benzydamine. Vet Approved Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Benzydamine. Approved Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Benzydamine. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when Benzydamine is combined with ME-609. Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Benzydamine. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when Benzydamine is combined with Medrysone. Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Benzydamine. Approved Melagatran Benzydamine may increase the anticoagulant activities of Melagatran. Experimental Melengestrol The risk or severity of adverse effects can be increased when Benzydamine is combined with Melengestrol. Vet Approved Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Benzydamine. Approved, Vet Approved Mepindolol Benzydamine may decrease the antihypertensive activities of Mepindolol. Experimental Mesalazine Benzydamine may increase the nephrotoxic activities of Mesalazine. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Benzydamine. Approved, Investigational, Withdrawn Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Benzydamine. Approved Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Benzydamine. Approved Methylprednisolone The risk or severity of adverse effects can be increased when Benzydamine is combined with Methylprednisolone. Approved, Vet Approved Metipranolol Benzydamine may decrease the antihypertensive activities of Metipranolol. Approved Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Benzydamine. Approved Metoprolol Benzydamine may decrease the antihypertensive activities of Metoprolol. Approved, Investigational Metrizamide Benzydamine may decrease the excretion rate of Metrizamide which could result in a higher serum level. Approved Micronomicin Benzydamine may decrease the excretion rate of Micronomicin which could result in a higher serum level. Experimental Mifamurtide The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Benzydamine. Approved, Experimental Misoprostol The therapeutic efficacy of Misoprostol can be decreased when used in combination with Benzydamine. Approved Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Benzydamine. Investigational Moexipril The risk or severity of adverse effects can be increased when Benzydamine is combined with Moexipril. Approved Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Benzydamine. Experimental Mometasone The risk or severity of adverse effects can be increased when Benzydamine is combined with Mometasone. Approved, Vet Approved Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with Benzydamine. Approved Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Benzydamine. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Benzydamine. Approved Nabumetone The risk or severity of adverse effects can be increased when Benzydamine is combined with Nabumetone. Approved Nadolol Benzydamine may decrease the antihypertensive activities of Nadolol. Approved Nadroparin Benzydamine may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Benzydamine may increase the anticoagulant activities of Nafamostat. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Benzydamine. Approved Nalidixic Acid Benzydamine may increase the neuroexcitatory activities of Nalidixic Acid. Approved, Investigational Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Benzydamine. Approved, Vet Approved NCX 1022 The risk or severity of adverse effects can be increased when Benzydamine is combined with NCX 1022. Investigational Neamine Benzydamine may decrease the excretion rate of Neamine which could result in a higher serum level. Experimental Nebivolol Benzydamine may decrease the antihypertensive activities of Nebivolol. Approved, Investigational Nemonoxacin Benzydamine may increase the neuroexcitatory activities of Nemonoxacin. Investigational Neomycin Benzydamine may decrease the excretion rate of Neomycin which could result in a higher serum level. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Benzydamine. Approved, Investigational Netilmicin Benzydamine may decrease the excretion rate of Netilmicin which could result in a higher serum level. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Benzydamine. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Benzydamine. Approved Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Benzydamine. Approved, Investigational, Withdrawn Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Benzydamine. Investigational Norfloxacin Benzydamine may increase the neuroexcitatory activities of Norfloxacin. Approved Oleoyl-estrone The risk or severity of adverse effects can be increased when Benzydamine is combined with Oleoyl-estrone. Investigational Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Benzydamine. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Benzydamine. Approved Olsalazine Benzydamine may increase the nephrotoxic activities of Olsalazine. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Benzydamine is combined with Omacetaxine mepesuccinate. Approved, Investigational Omapatrilat The risk or severity of adverse effects can be increased when Benzydamine is combined with Omapatrilat. Investigational Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Benzydamine. Vet Approved Otamixaban Benzydamine may increase the anticoagulant activities of Otamixaban. Investigational Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Benzydamine. Approved Oxolinic acid Benzydamine may increase the neuroexcitatory activities of Oxolinic acid. Experimental Oxprenolol Benzydamine may decrease the antihypertensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Benzydamine. Approved, Withdrawn Pamidronate The risk or severity of adverse effects can be increased when Benzydamine is combined with Pamidronate. Approved Paramethasone The risk or severity of adverse effects can be increased when Benzydamine is combined with Paramethasone. Approved Parecoxib The risk or severity of adverse effects can be increased when Benzydamine is combined with Parecoxib. Approved Paromomycin Benzydamine may decrease the excretion rate of Paromomycin which could result in a higher serum level. Approved, Investigational Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Benzydamine. Approved, Investigational Pazufloxacin Benzydamine may increase the neuroexcitatory activities of Pazufloxacin. Investigational Pefloxacin Benzydamine may increase the neuroexcitatory activities of Pefloxacin. Approved Penbutolol Benzydamine may decrease the antihypertensive activities of Penbutolol. Approved, Investigational Pentaerythritol Tetranitrate Benzydamine may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate Benzydamine may increase the anticoagulant activities of Pentosan Polysulfate. Approved Perindopril The risk or severity of adverse effects can be increased when Benzydamine is combined with Perindopril. Approved Phenindione Benzydamine may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Benzydamine may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Benzydamine. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benzydamine. Approved, Investigational Pindolol Benzydamine may decrease the antihypertensive activities of Pindolol. Approved, Investigational Pipemidic acid Benzydamine may increase the neuroexcitatory activities of Pipemidic acid. Experimental Pirarubicin Benzydamine may decrease the excretion rate of Pirarubicin which could result in a higher serum level. Investigational Piretanide The therapeutic efficacy of Piretanide can be decreased when used in combination with Benzydamine. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Benzydamine. Approved, Investigational Piromidic acid Benzydamine may increase the neuroexcitatory activities of Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Benzydamine. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Benzydamine. Experimental Pitolisant The risk or severity of adverse effects can be increased when Benzydamine is combined with Pitolisant. Approved, Investigational Platelet Activating Factor Benzydamine may decrease the antihypertensive activities of Platelet Activating Factor. Experimental Plazomicin Benzydamine may decrease the excretion rate of Plazomicin which could result in a higher serum level. Investigational Plicamycin Benzydamine may decrease the excretion rate of Plicamycin which could result in a higher serum level. Approved, Investigational, Withdrawn Polythiazide The therapeutic efficacy of Polythiazide can be decreased when used in combination with Benzydamine. Approved Practolol Benzydamine may decrease the antihypertensive activities of Practolol. Approved Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Benzydamine. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Benzydamine. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Benzydamine is combined with Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Benzydamine is combined with Prasterone sulfate. Investigational Prednicarbate The risk or severity of adverse effects can be increased when Benzydamine is combined with Prednicarbate. Approved, Investigational Prednisolone The risk or severity of adverse effects can be increased when Benzydamine is combined with Prednisolone. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Benzydamine is combined with Prednisone. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Benzydamine is combined with Pregnenolone. Approved, Experimental, Investigational Probenecid The serum concentration of Benzydamine can be increased when it is combined with Probenecid. Approved, Investigational Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Benzydamine. Experimental Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Benzydamine. Approved, Investigational Propranolol Benzydamine may decrease the antihypertensive activities of Propranolol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Benzydamine. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Benzydamine. Experimental Prostaglandin B2 The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Benzydamine. Experimental Prostaglandin G2 The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Benzydamine. Experimental Prostalene The therapeutic efficacy of Prostalene can be decreased when used in combination with Benzydamine. Vet Approved Protein C Benzydamine may increase the anticoagulant activities of Protein C. Approved Protein S human Benzydamine may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Benzydamine may increase the anticoagulant activities of Protocatechualdehyde. Approved Prulifloxacin Benzydamine may increase the neuroexcitatory activities of Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Benzydamine. Investigational Puromycin Benzydamine may decrease the excretion rate of Puromycin which could result in a higher serum level. Experimental Quinapril The risk or severity of adverse effects can be increased when Benzydamine is combined with Quinapril. Approved, Investigational Quinethazone The therapeutic efficacy of Quinethazone can be decreased when used in combination with Benzydamine. Approved Ramipril The risk or severity of adverse effects can be increased when Benzydamine is combined with Ramipril. Approved Rescinnamine The risk or severity of adverse effects can be increased when Benzydamine is combined with Rescinnamine. Approved Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Benzydamine. Approved, Experimental, Investigational Reviparin Benzydamine may increase the anticoagulant activities of Reviparin. Approved, Investigational Ribostamycin Benzydamine may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Approved, Investigational Rimexolone The risk or severity of adverse effects can be increased when Benzydamine is combined with Rimexolone. Approved Risedronate The risk or severity of adverse effects can be increased when Benzydamine is combined with Risedronate. Approved, Investigational Rivaroxaban Benzydamine may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib The risk or severity of adverse effects can be increased when Benzydamine is combined with Rofecoxib. Approved, Investigational, Withdrawn Rosoxacin Benzydamine may increase the neuroexcitatory activities of Rosoxacin. Approved, Investigational Rufloxacin Benzydamine may increase the neuroexcitatory activities of Rufloxacin. Experimental Sabarubicin Benzydamine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Benzydamine. Approved Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Benzydamine. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Benzydamine. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Benzydamine. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Benzydamine. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Benzydamine. Investigational Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Benzydamine. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Benzydamine. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Benzydamine. Investigational Sisomicin Benzydamine may decrease the excretion rate of Sisomicin which could result in a higher serum level. Investigational Sitafloxacin Benzydamine may increase the neuroexcitatory activities of Sitafloxacin. Experimental, Investigational Sodium phosphate Sodium phosphate may increase the nephrotoxic activities of Benzydamine. Approved Sotalol Benzydamine may decrease the antihypertensive activities of Sotalol. Approved SP1049C Benzydamine may decrease the excretion rate of SP1049C which could result in a higher serum level. Investigational Sparfloxacin Benzydamine may increase the neuroexcitatory activities of Sparfloxacin. Approved, Investigational Spectinomycin Benzydamine may decrease the excretion rate of Spectinomycin which could result in a higher serum level. Approved, Investigational, Vet Approved Spirapril The risk or severity of adverse effects can be increased when Benzydamine is combined with Spirapril. Approved Spironolactone Benzydamine may decrease the antihypertensive activities of Spironolactone. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Benzydamine. Investigational Streptomycin Benzydamine may decrease the excretion rate of Streptomycin which could result in a higher serum level. Approved, Vet Approved Streptozocin Benzydamine may decrease the excretion rate of Streptozocin which could result in a higher serum level. Approved, Investigational Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Benzydamine. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Benzydamine. Approved, Investigational Sulodexide Benzydamine may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sulprostone The therapeutic efficacy of Sulprostone can be decreased when used in combination with Benzydamine. Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Benzydamine. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Benzydamine. Experimental Tacrolimus Benzydamine may increase the nephrotoxic activities of Tacrolimus. Approved, Investigational Tafluprost The therapeutic efficacy of Tafluprost can be decreased when used in combination with Benzydamine. Approved Talinolol Benzydamine may decrease the antihypertensive activities of Talinolol. Investigational Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with Benzydamine. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Benzydamine. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Benzydamine. Approved Technetium Tc-99m etidronate The risk or severity of adverse effects can be increased when Benzydamine is combined with Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate The risk or severity of adverse effects can be increased when Benzydamine is combined with Technetium Tc-99m medronate. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Benzydamine. Approved, Investigational Temafloxacin Benzydamine may increase the neuroexcitatory activities of Temafloxacin. Withdrawn Temocapril The risk or severity of adverse effects can be increased when Benzydamine is combined with Temocapril. Experimental, Investigational Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Benzydamine. Experimental Tenofovir disoproxil The risk or severity of adverse effects can be increased when Benzydamine is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Benzydamine. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Benzydamine. Vet Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Benzydamine. Approved Tertatolol Benzydamine may decrease the antihypertensive activities of Tertatolol. Experimental Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Benzydamine. Approved Tiludronic acid The risk or severity of adverse effects can be increased when Benzydamine is combined with Tiludronic acid. Approved, Investigational, Vet Approved Timolol Benzydamine may decrease the antihypertensive activities of Timolol. Approved Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Benzydamine. Investigational Tixocortol The risk or severity of adverse effects can be increased when Benzydamine is combined with Tixocortol. Approved, Withdrawn Tobramycin Benzydamine may decrease the excretion rate of Tobramycin which could result in a higher serum level. Approved, Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Benzydamine. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Benzydamine. Approved Torasemide The therapeutic efficacy of Torasemide can be decreased when used in combination with Benzydamine. Approved Trandolapril The risk or severity of adverse effects can be increased when Benzydamine is combined with Trandolapril. Approved Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Benzydamine. Approved, Investigational Travoprost The therapeutic efficacy of Travoprost can be decreased when used in combination with Benzydamine. Approved Treprostinil The risk or severity of adverse effects can be increased when Treprostinil is combined with Benzydamine. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Benzydamine is combined with Triamcinolone. Approved, Vet Approved Triamterene Benzydamine may decrease the antihypertensive activities of Triamterene. Approved Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Benzydamine. Experimental Trichlormethiazide The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Benzydamine. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Benzydamine. Investigational Trovafloxacin Benzydamine may increase the neuroexcitatory activities of Trovafloxacin. Approved, Investigational, Withdrawn Troxerutin Benzydamine may increase the anticoagulant activities of Troxerutin. Investigational Ulobetasol The risk or severity of adverse effects can be increased when Benzydamine is combined with Ulobetasol. Approved Unoprostone The therapeutic efficacy of Unoprostone can be decreased when used in combination with Benzydamine. Approved, Investigational Valdecoxib The risk or severity of adverse effects can be increased when Benzydamine is combined with Valdecoxib. Approved, Investigational, Withdrawn Valrubicin Benzydamine may decrease the excretion rate of Valrubicin which could result in a higher serum level. Approved Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Benzydamine. Approved, Investigational Vancomycin The serum concentration of Vancomycin can be increased when it is combined with Benzydamine. Approved Warfarin Benzydamine may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Benzydamine may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Benzydamine. Approved, Investigational Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Benzydamine. Approved, Investigational, Withdrawn Zofenopril The risk or severity of adverse effects can be increased when Benzydamine is combined with Zofenopril. Experimental Zoledronic acid The risk or severity of adverse effects can be increased when Benzydamine is combined with Zoledronic acid. Approved Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Benzydamine. Withdrawn Zoptarelin doxorubicin Benzydamine may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level. Investigational Zorubicin Benzydamine may decrease the excretion rate of Zorubicin which could result in a higher serum level. Experimental - Food Interactions
- Not Available
References
- General References
- Baldock GA, Brodie RR, Chasseaud LF, Taylor T, Walmsley LM, Catanese B: Pharmacokinetics of benzydamine after intravenous, oral, and topical doses to human subjects. Biopharm Drug Dispos. 1991 Oct;12(7):481-92. [PubMed:1932611]
- Silvestrini B, Barcellona PS, Garau A, Catanese B: Toxicology of benzydamine. Toxicol Appl Pharmacol. 1967 Jan;10(1):148-59. [PubMed:6031923]
- Quane PA, Graham GG, Ziegler JB: Pharmacology of benzydamine. Inflammopharmacology. 1998;6(2):95-107. doi: 10.1007/s10787-998-0026-0. [PubMed:17694367]
- Catanese B, Grasso A, Silverstrini B: Studies on the absorption and elimination of benzydamine in the mouse, rat, dog, and man. Arzneimittelforschung. 1966 Oct;16(10):1354-7. [PubMed:6014929]
- Electronic Medicines Compedium Difflam (Benzydamine Hydrochloride) Spray Monograph [Link]
- Electronic Medicines Compedium Benzydamine Hydrochloride 0.15% w/v Mouthwash Monograph [Link]
- Electronic Medicines Compedium Difflam (Benzydamine Hydrochloride) 3% Cream Monograph [Link]
- External Links
- PubChem Compound
- 12555
- PubChem Substance
- 310265011
- ChemSpider
- 12036
- BindingDB
- 50095471
- ChEBI
- 94563
- ChEMBL
- CHEMBL12610
- Wikipedia
- Benzydamine
- ATC Codes
- M01AX07 — Benzydamine
- M01AX — Other antiinflammatory and antirheumatic agents, non-steroids
- M01A — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
- M01 — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
- M — MUSCULO-SKELETAL SYSTEM
- M02AA — Antiinflammatory preparations, non-steroids for topical use
- M02A — TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
- M02 — TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
- M — MUSCULO-SKELETAL SYSTEM
- A01AD — Other agents for local oral treatment
- A01A — STOMATOLOGICAL PREPARATIONS
- A01 — STOMATOLOGICAL PREPARATIONS
- A — ALIMENTARY TRACT AND METABOLISM
- AHFS Codes
- 52:28.00 — Mouthwashes and Gargles
- 52:08.20 — Nonsteroidal Anti-inflammatory Agents
- MSDS
- Download (343 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Supportive Care Head and Neck Carcinoma / Mucositis 1 3 Unknown Status Prevention For Intervention 1 4 Completed Other Intubation Complications 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Liquid Buccal 0.15 % Mouthwash; solution Buccal; Oral 1.5 mg Liquid; mouthwash Buccal; Oral 1.5 mg Mouthwash Buccal 1.5 mg Solution Oral 0.15 % Liquid Dental; Oral .15 % Solution Buccal 15 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 320°F MSDS water solubility Miscible MSDS - Predicted Properties
Property Value Source Water Solubility 0.0491 mg/mL ALOGPS logP 3.78 ALOGPS logP 3.66 ChemAxon logS -3.8 ALOGPS pKa (Strongest Basic) 9.26 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 30.29 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 105.56 m3·mol-1 ChemAxon Polarizability 35.62 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as indazoles. These are compounds containing an indazole, which is structurally characterized by a pyrazole fused to a benzene.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzopyrazoles
- Sub Class
- Indazoles
- Direct Parent
- Indazoles
- Alternative Parents
- Alkyl aryl ethers / Benzene and substituted derivatives / Pyrazoles / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Benzopyrazole / Indazole / Alkyl aryl ether / Monocyclic benzene moiety / Benzenoid / Azole / Pyrazole / Heteroaromatic compound / Tertiary amine / Tertiary aliphatic amine
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Drug created on September 15, 2015 13:55 / Updated on April 17, 2018 01:10